A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)
Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Listed as NCT06226883, this observational or N/A phase trial focuses on Crohn's Disease and Inflammatory Bowel Diseases and remains actively recruiting participants. Sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), it has been updated 23 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of induction therapy with 3 active dose regimens of MORF-057 versus matching placebo in adult study participants with moderately to severely active CD. After completion of the 14-week Induction Period, all participants will receive open-label MORF-057 during the 38-week Maintenance Period. All participants who complete the full 52-week Treatment Period will also have the opportunity to continue treatment in a 52-week Long-Term Extension.
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of induction therapy with 3 active dose regimens of MORF-057 versus matching placebo in adult study participants with moderately to severely active CD. After completion of the 14-week Induction Period, all participants will receive open-label MORF-057 during the 38-week Maintenance Period. All participants who complete the full 52-week Treatment Period will also have the opportunity to continue treatment in a 52-week Long-Term Extension.
Status Flow
Change History
23 versions recorded-
Apr 18, 2026 — Present [daily]
Recruiting
Phase: PHASE2 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
▶ Show 18 earlier versions
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Contact Information
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Almaty, Kazakhstan , Aracaju, Brazil , Armenia, Colombia , Asahikawa, Japan , Astana, Kazakhstan , Astana, Kazakhstan , Atlanta, United States , Atlanta, United States , Batumi, Georgia and 205 more locations